J Korean Med Sci.  2011 Feb;26(2):191-195. 10.3346/jkms.2011.26.2.191.

Immunogenicity and Safety of Trivalent Inactivated Influenza Vaccine: A Randomized, Double-Blind, Multi-Center, Phase 3 Clinical Trial in a Vaccine-Limited Country

• Song JY
• Cheong HJ
• Woo HJ
• Wie SH
• Lee JS
• Chung MH
• Kim YR
• Jung SI
• Park KH
• Kim TH
• Uh ST
• Kim WJ

• KMID: 1782105
• DOI: http://doi.org/10.3346/jkms.2011.26.2.191

Abstract

Influenza vaccines are the primary method for controlling influenza and its complications. This study was conducted as a phase 3, randomized, double-blind, controlled, multi-center trial at seven university hospitals to evaluate the immunogenicity and safety of an inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin, Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26, a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976 subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA criteria with > or = 80% of subjects achieving post-vaccination titers > or = 40 for all three subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and local adverse events. In summary, GC501 showed excellent immunogenicity and a good safety profile in both young adults and the elderly. The licensure of GC501 might be an important basis in preparation for the future influenza pandemic.

Keyword

Influenza Vaccines; Influenza, Human; Vaccines, Inactivated

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Double-Blind Method
Humans
Influenza Vaccines/administration & dosage/*adverse effects/*immunology
Influenza, Human/*prevention & control
Male
Middle Aged
Republic of Korea
Vaccination
Vaccines, Inactivated/administration & dosage/adverse effects/immunology
Young Adult

Figure

• 

  Fig. 1 Flowchart of subjects through the study.

Reference

1. Wilschut JC, McElhaney J, Palache B. Influenza. 2006. 2nd ed. Philadelphia, PA: Elsevier Ltd;117–132.

2. Park SC, Choeng HJ, Sohn JW, Choi SJ, Eom JS, Woo HJ, Chun BC, Kim WJ. Efficacy of influenza vaccination among chronic ill patients: retrospective case control study. Infect Chemother. 2004. 36:207–212.

3. Lee JS, Shin KC, Na BK, Lee JY, Kang C, Kim JH, Park O, Jeong EK, Lee JK, Kwon JW, Park SC, Kim WJ. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect. 2007. 135:1117–1123.

4. Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, Jo YM, Seo YB, Kim WJ. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect. 2007. 55:273–281.

5. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine. 2010. 28:3929–3935.

6. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). European Committee for Proprietary Medicinal Products. c1997. accessed on 17 Aug 2010. London, UK: The Europen Agency for the Evaluation of Medicinal Products;Available at http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf.

7. Guidance for industry: clinical data needed to support the licensure of trivalent inactivated influenza vaccines. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. c2006. accessed on 17 Aug 2010. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf.

8. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. U.S. Department of Health and Human Services FDA, Center for Biologics Evaluation and Research. 2007. accessed on 17 Aug 2010. Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRe.

9. El Sahly HM, Keitel WA. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008. 7:713–719.

10. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis. 2003. 36:1552–1561.

11. Cheong HJ. Safety of influenza vaccine. J Korean Med Assoc. 2007. 50:267–273.